Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1101
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 733–744 of 1,101 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904
Site status not listed — check the official record
View directory record Official record
Conditions
Langerhans Cell Histiocytosis
Interventions
Clofarabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381
Status at this site: Recruiting
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Pelacarsen (TQJ230) 80mg, Matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
35
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Not applicable Interventional

The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)

NCT05820087
Site status not listed — check the official record
View directory record Official record
Conditions
Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
Interventions
HistoSonics Edison System
Device
Lead sponsor
HistoSonics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Los Angeles, California • Mission Viejo, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
Status at this site: Recruiting
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Not applicable Interventional

DBS for TRD With the Medtronic Summit RC+S

NCT04106466
Site status not listed — check the official record
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Summit RC+S DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

NCT06263426
Status at this site: Recruiting
View directory record Official record
Conditions
Hiv
Interventions
HIV D-/R+
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting Phase 1 Interventional

Assessing the Safety and Tolerability of NMN in DHDDS-CDG

NCT07572825
Status at this site: Recruiting
View directory record Official record
Conditions
DHDDS-Congenital Disorder of Glycosylation, DHDDS-CDG, Congenital Disorder of Glycosylation
Interventions
Nicotinamide Mononucleotide (NMN) Nucleosidase
Drug
Lead sponsor
Eva Morava-Kozicz
Other
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

A Multi Center Study of Sexual Toxicities After Radiotherapy

NCT05394428
Status at this site: Recruiting
View directory record Official record
Conditions
Malignant Neoplasms
Interventions
No intervention
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting Not applicable Interventional

Paired Vagus Nerve Stimulation in Mobilization of Patients With Prolonged Disorders of Consciousness

NCT06930716
Status at this site: Recruiting
View directory record Official record
Conditions
Consciousness Disorders, Brain Injury, Altered Level of Consciousness
Interventions
Transcutaneous vagus nerve stimulation (taVNS), Physical therapy using Hocoma, Standard of Care
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340
Site status not listed — check the official record
View directory record Official record
Conditions
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
55
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting No phase listed Observational

Environmental Factors and Thyroid Cancer

NCT05172921
Status at this site: Recruiting
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 10:27 AM EDT
Recruiting Phase 2 Interventional

Regeneron AA Multicenter (Dupilumab)

NCT05551793
Status at this site: Recruiting
View directory record Official record
Conditions
Alopecia Areata
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Irvine, California • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 10:27 AM EDT

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.